Company Encyclopedia
View More
name
Blueprint Med
BPMC.US
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers.
1.946 T
BPMC.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking0/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-47.71%E
    • Profit Margin-27.70%E
    • Gross Margin98.12%A
  • Growth ScoreA
    • Revenue YoY99.19%A
    • Net Profit YoY45.98%B
    • Total Assets YoY15.13%A
    • Net Assets YoY10.12%B
  • Cash ScoreC
    • Cash Flow Margin-360.96%D
    • OCF YoY99.19%A
  • Operating ScoreC
    • Turnover0.5C
  • Debt ScoreD
    • Gearing Ratio71.38%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Highly competitive KIT inhibitors market with key players like ONO Pharmaceutical and Blueprint Medicines. Expect growth in 7MM by 2034.

    Competition in the market for KIT inhibitors is fierce, with key industry players including ONO Pharmaceutical and Blueprint Medicines leading the way. Meanwhile, Celldex Therapeutics, Cogent Biosciences, and Blueprint Medicines are making significant strides in the sector. The market is marked by intense rivalry, with a focus on innovation and market positioning.

    Unusual Whales·
    US
    BPMC
    0.00%
    US
    OPHLY
    -0.44%
    US
    COGT
    +0.38%
    Unusual Whales·
    US
    BPMC
    0.00%
    US
    OPHLY
    -0.44%
    US
    COGT
    +0.38%

    Sanofi (SNY) Expands Rare Disease Reach With $9.5B Blueprint Deal

    Sanofi (SNY) has announced a significant acquisition of Blueprint Medicines for $9.5 billion, enhancing its position in rare immunological diseases. This deal adds the only approved treatment for systemic mastocytosis and promising pipeline assets to Sanofi's portfolio. The acquisition aligns with Sanofi's goal to strengthen its immunology division and follows its success with Dupixent. Additionally, the company plans to invest $20 billion in the U.S. by 2030 to boost R&D and manufacturing capabilities.

    insidermonkey·
    US
    BPMC
    0.00%
    US
    SNYNF
    0.00%
    insidermonkey·
    US
    BPMC
    0.00%
    US
    SNYNF
    0.00%

    Blueprint Medicines Completes $9.1B Merger, Delists from Nasdaq

    Blueprint Medicines has completed a $9.1 billion merger, resulting in the delisting of its shares from Nasdaq. The merger involved the prepayment and termination of existing financial agreements and changes in the board of directors. Analysts rate BPMC stock as a Buy with a $125 price target, though concerns about profitability and valuation persist. The overall sentiment is Neutral, with strong growth potential but caution advised due to overbought conditions.

    Tip Ranks·
    US
    BPMC
    0.00%
    Tip Ranks·
    US
    BPMC
    0.00%

    Sanofi to Acquire Blueprint Medicines Corporation Following Successful Tender Offer Completion

    Sanofi is set to acquire Blueprint Medicines Corporation following the successful completion of a tender offer by its subsidiary, Rothko Merger Sub, Inc. The merger will result in Blueprint Medicines becoming a wholly-owned subsidiary of Sanofi, with the latter remaining the surviving corporation post-merger. This announcement highlights a significant corporate event in the pharmaceutical industry.

    Reuters·
    US
    SNYNF
    0.00%
    US
    BPMC
    0.00%
    Reuters·
    US
    SNYNF
    0.00%
    US
    BPMC
    0.00%

    Sanofi completes acquisition of biopharmaceutical company Blueprint for over $9 billion

    On July 18th, Sanofi announced the completion of its acquisition of the American biopharmaceutical company Blueprint Medicines. This acquisition includes a rare immune disease drug Ayvakit/Ayvakyt (avapritinib), which has been approved in the United States and the European Union. According to the acquisition terms announced in June this year, Sanofi will pay $129 in cash per share, with an equity value of approximately $9.1 billion. (Jiemian)

    36Kr·
    US
    BPMC
    0.00%
    US
    SNYNF
    0.00%
    US
    SNY
    -1.59%
    36Kr·
    US
    BPMC
    0.00%
    US
    SNYNF
    0.00%
    US
    SNY
    -1.59%
    © 2025 Longbridge｜Disclaimer